Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis

NCT06611163 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT06611163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06611163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 21, 2025
Completion date
February 28, 2027
Enrollment
206 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe genital psoriasis